###### Strengths and limitations of this study

-   This study is the first randomised trial of near-infrared spectroscopy-derived StO~2~-guided resuscitation in sepsis or septic shock.

-   The trial was performed in five major intensive care units in four European countries.

-   High standards to limit the risk of selection, such as consensus definition for sepsis and appropriate allocation concealment, and performance biases, including strict implementation of the 2004 Surviving Sepsis Campaign guidelines were used.

-   Study limitations included the lack of assessor blinding for the primary outcome and its premature termination, which reduced the power.

Introduction {#s1}
============

Near-infrared spectroscopy (NIRS) is based on the capacity of different chromophores in tissues to absorb light in the 700--1000 nm wavelength range. Analysis of the light emitted and received provides a non-invasive and continuous semiquantitative calculation of the ratio of oxyhaemoglobin to total haemoglobin in skeletal muscle (ie, the tissue oxygen saturation or skeletal muscle tissue oxygenation). Basal StO~2~ values of 86%±6% were reported in the thenar prominence (Thenar-StO~2~) in healthy volunteers. Evaluation of StO~2~ using NIRS may aid in the monitoring of patients with sepsis or septic shock.[@R1] A low StO~2~ value during sepsis may be associated with poor clinical outcomes[@R3] and reflect altered microcirculatory perfusion.[@R7] StO~2~ values under 75% in septic patients were associated with poor outcomes.[@R1] However, there is important overlap between pathological values and the values obtained under normal conditions.[@R1] The 2004 guidelines for the management of sepsis recommended early quantitative resuscitation protocolised care based on a set of central haemodynamic targets, including mean arterial pressure (MAP), heart rate, urinary output, central venous pressure (CVP) and global indices of tissue hypoperfusion (ie, central venous oxygen saturation and/or lactate clearance).[@R8] The Surviving Sepsis Campaign guidelines do not include recommendations for monitoring or targeting the microcirculation, but interventions, such as inotropes and blood products transfusion, may affect sepsis survival.[@R8] Some patients continue to exhibit altered microcirculation, for example, low StO~2~ associated with poor clinical outcomes, despite completion of early quantitative protocolised care.[@R6] Our previous pilot study evaluated the feasibility of targeting the microcirculation via monitoring of StO~2~ at multiple sites in patients who completed a 6-hour bundle of the Surviving Sepsis Campaign.[@R12] The present European, multicentre, randomised trial (the Optimization of Tissue Oxygenation-StO~2~ in Sepsis Study) assessed the benefits and risks of targeting StO~2~ in adults with severe sepsis who were managed according to the 6-hour bundle of the 2004 Surviving Sepsis Campaign. Our hypothesis was that StO~2~ evaluation would aid in the detection of patients who remained under-resuscitated after completion of early goal-directed therapy, and further StO~2~-guided haemodynamic treatment may improve their clinical outcomes.

Materials and methods {#s2}
=====================

Study design {#s2a}
------------

The ethics committees of the participating institutions in France (n=2), Greece (n=1), Spain (n=1) and Germany (n=1) approved the protocol for this multicentre, randomised, non-blinded phase II/III trial. Recruitment into the trial began in February 2006 and ended in May 2009. An independent safety, efficacy and data-monitoring committee reviewed the study protocol prior to the initiation of recruitment and periodically reviewed the accumulated study data. All authors contributed to the design of the study, recruitment of patients, and data collection and interpretation. The sponsor had no role in the design or conduct of the study, in the collection, management, analysis, or interpretation of the data, or the preparation, review, approval or submission of the manuscript. This trial is registered at ClinicalTrials.gov under NCT00167596.

Patients {#s2b}
--------

Patients with suspected or confirmed sources of infection were considered for enrolment in this study if they were 18 years of age or older, admitted to the intensive care unit (ICU), met two or more of the Systemic Immune Response Syndrome criteria[@R13] and exhibited at least one of the following signs of tissue hypoperfusion: (1) a systolic blood pressure of 90 mm Hg or less; (2) arterial lactate level of 4 mmol/L or more; (3) mottled skin; (4) urine output below 30 mL/hour for at least 1 hour; and (5) altered mental status. The time window for inclusion was less than 8 hours from the onset of the first sign of hypoperfusion. Patients younger than 18 years, pregnant women, brain-dead patients and patients who decided to withhold or withdraw from life-supporting treatments were not eligible.

Randomisation (1:1 ratio) was stratified according to the study centre and balanced by blocks of 4 using a computerised random number generator list provided by an independent statistician. Sequentially numbered, sealed and opaque envelopes were used. Each envelope was assigned to a patient and opened only after the investigator wrote the patient's information on it and faxed the signed inclusion sheet with the patient's randomisation details to the coordinating centre. This procedure allowed for the monitoring of treatment allocation to unique patients in an appropriate order.

Interventions {#s2c}
-------------

Subjects were managed using an algorithm that was adapted from the 2004 Surviving Sepsis Campaign guidelines.[@R14] Briefly, patients received 500 mL of crystalloids or colloids every 30 min until their CVP was between 8 and 12 mm Hg. Vasopressor therapy (norepinephrine or epinephrine) was initiated if the MAP remained lower than 65 mm Hg, using titration until an MAP of 65--80 mm Hg was reached. Packed red blood cells were transfused if the central venous oxygen saturation (ScvO~2~) was lower than 70% and haematocrit levels were lower than 30%. Dobutamine was initiated at a dose of 2.5 µg/kg/min if the ScvO~2~ was lower than 70% and the haematocrit levels were higher than 30%. Dobutamine was titrated in incremental steps of 2.5 µg/kg/min every 30 min until the ScvO~2~ level was 70% or greater without exceeding an infusion rate of 20 µg/kg/min. The dobutamine infusion rate was kept constant as soon as all of the haemodynamic goals were achieved or decreased whenever the heart rate exceeded 120/min. The CVP, MAP and ScvO~2~ were optimised in the StO~2~ arm, and the interventions ([figure 1](#F1){ref-type="fig"}) targeted StO~2~ values of 80% or greater in at least two muscular sites in the thenar, masseter and deltoid areas.

![Haemodynamic treatment algorithm. CVP, central venous pressure; Ht, haematocrit; MBP, mean blood pressure.](bmjopen-2017-017581f01){#F1}

ScvO~2~ and StO~2~ recordings {#s2d}
-----------------------------

All patients had an arterial line placed in the radial or femoral artery and a catheter in the superior vena cava. The ScvO~2~ and StO~2~ levels were recorded at baseline (H0) and at H2, H4, H6 and H24 following randomisation. StO~2~ was recorded using an InSpectra Tissue Spectrometer (InSpectra 650 StO~2~ Tissue Oxygenation Monitor, Hutchinson Technology, MN, USA) and 25 mm probes placed over the left thenar eminence (Thenar-StO~2~), left masseter muscle (Masseter-StO~2~) and left deltoid muscle (Deltoid-StO~2~) as described by Colin *et al*.[@R3] Measurements of the Thenar-StO~2~ ipsilateral to a radial arterial line were collected. The StO~2~ values were sequentially collected after 2 min of stable recording in the masseter, deltoid and thenar areas. Calibration of the spectrometer was performed once before monitoring as recommended by the manufacturer. Adhesive shields were kept in place throughout the duration of the experiments. The StO~2~ was recorded in the control group and masked throughout the study period to the investigators and medical and nursing staff members.

Data collection and follow-up {#s2e}
-----------------------------

The patients' prior locations (ie, community, hospital or long-term care facility), Knaus categorisation of health status,[@R15] McCabe class,[@R16] severity of illness as assessed by vital signs, Simplified Acute Physiology Score II,[@R17] Sepsis-related Organ Failure Assessment (SOFA) score,[@R18] type and dose of any intervention, routine laboratory data, arterial blood lactates and cultures of samples collected at any suspected site of infection were recorded on admission.

The vital status of the patients was followed up to 30 days from randomisation. The type and dose of any intervention, ScvO~2~, and StO~2~ at H0, H2, H4, H6 and H24 were systematically recorded during the first 24 hours after randomisation. The SOFA score was recorded each morning from randomisation to day 7 of the study.

Endpoints {#s2f}
---------

The primary outcome was a composite endpoint of all-cause mortality on day 7 and deterioration in organ function as defined by a positive difference in the SOFA score between study day 7 and baseline (ie, delta SOFA \>0).

The secondary endpoints included 30-day all-cause mortality, duration of mechanical ventilation and the use of vasopressors within 30 days after randomisation. Outcomes were assessed in a non-blinded manner.

Statistical analysis {#s2g}
--------------------

### Sample size {#s2g1}

A total of 95 patients must be included in each arm to achieve a statistical power of 80%, considering that an absolute 20% difference in the main criterion would be clinically significant and the main criterion would be reached in 50% of the patients in the control group. However, the study ended after inclusion of 54 patients in the experimental group and 49 patients in the control group, which reduced the study power. The corresponding power to detect a 20% absolute difference if the main criterion was reached in 50% of the patients in the control group was only 54%.

### Descriptive statistics {#s2g2}

Continuous variables are reported as the means plus or minus SD or medians and IQR in cases of non-normality in variable distribution. Categorical variables are reported as numbers and percentages.

### Comparative analyses {#s2g3}

We performed intent-to-treat analysis after completion of the last follow-up of the last recruited patients. We did not plan interim analyses. We did not plan formal statistical comparisons of baseline characteristics because of the randomisation of treatment allocation. The primary outcome (composite endpoint of all-cause mortality on day 7 and deterioration in organ function as defined by a delta SOFA \>0) was compared between groups by χ^2^ tests, and relative risk and absolute difference with 95% CIs were computed. Comparisons of secondary outcomes (duration of treatment with vasopressors, duration of mechanical ventilation and mortality on day 30) were performed using χ^2^ tests, and relative risks with 95% CIs were computed. Survival curves until day 30 were created using the Kaplan-Meier method and compared using the log-rank test. We also performed post hoc statistical analyses to compute univariate and multivariate ORs of mechanical ventilation on day 7. All tests were two sided, and the differences were significant when P values were lower than 0.05.

Results {#s3}
=======

Patients {#s3a}
--------

The sponsor of this study withdrew support for the trial in May 2009 as a consequence of the global economic crisis. The trial was stopped as a result of the cessation of funding. A total of 103 patients (54% of the 190 planned) were enrolled at the study termination.

A total of 555 patients were screened for enrolment in this study from February 2006 to May 2009. A total of 103 of the 143 eligible patients, or their next of kin, provided written informed consent. Fifty-four patients were randomly assigned to the experimental arm, and 49 patients were assigned to the control arm ([figure 2](#F2){ref-type="fig"}). Patient characteristics and demographics of the two groups were well matched at baseline ([table 1](#T1){ref-type="table"}). The lungs were the most common source of infection (52.5%), and 16% of the patients exhibited positive blood cultures. Eighty-six per cent of the patients in the StO~2~ group and 85% in the control group were on mechanical ventilation at inclusion.

![Study flow diagram.](bmjopen-2017-017581f02){#F2}

###### 

Main characteristics of the 103 patients

  Variable                               Experimental arm   Control arm
  -------------------------------------- ------------------ -------------
  Expected number of patients            95                 95
  Actual number of patients              54                 49
  Age (year)                             65.6±16            60.8±18
  Sex (%)                                                   
   Female                                33.3               32.7
   Male                                  66.6               67.3
  BMI (kg/m²)                            25±3               24±4
  McCabe score (%)                                          
   No underlying or non-fatal disease    66.6               71.4
   Fatal disease (\<5 years)             25.9               26.5
   Rapidly fatal disease (\<1 year)      5.5                0
  Knaus                                                     
   No limitation                         44.4               40.8
   Moderate activity limitation          25.9               28.6
   Severe activity limitation            16.7               26.5
   Bedridden patient                     13.0               4.1
  SAPSII                                 48±23              51±18
  SOFA on ICU admission                  10±4               9±4
  Source of infection (%)                                   
   Lung                                  51.9               53.1
   Abdominal                             20.4               14.3
   Urogenital                            14.8               18.3
  Sepsis type (%)                                           
   Nosocomial                            35.2               42.9
   Community acquired                    64.8               57.1
  Positive blood culture (%)             14.8               16.3
  Corticosteroids, n (%)                 31 (57)            26 (53)
  Activated protein C treatment, n (%)   8 (15)             3 (6)

The plus-minus values are the means±SDs.

BMI, body mass index; ICU, intensive care unit; SAPSII, Simplified Acute Physiology Score II; SOFA, Sepsis-related Organ Failure Assessment.

Resuscitation endpoints {#s3b}
-----------------------

Only 27 (26%) patients, 15 in the experimental arm and 12 in the control arm, exhibited ScvO~2~ values below 70% at baseline ([table 2](#T2){ref-type="table"}). In contrast, 67 (65%) patients, 32 in the experimental arm and 35 in the control arm, exhibited StO~2~ values less than 80% at two or more muscular sites. No significant differences between the two study groups were observed in any of the haemodynamic variables or lactate levels during the first 6 hours after randomisation ([table 2](#T2){ref-type="table"}). The interventions delivered to the patients in the experimental arm did not produce the intended effect on StO~2~, with almost one-fourth of the patients unable to achieve the target of StO~2~ \>80% at ≥2 sites ([table 2](#T2){ref-type="table"}).

###### 

Vital signs, resuscitation goals

  Variable and treatment group      Expected number of patients   Actual number of patients   Baseline   Hours after start of therapy              
  --------------------------------- ----------------------------- --------------------------- ---------- ------------------------------ ---------- ----------
  Systolic blood pressure (mm Hg)                                                                                                                  
   Experimental arm                 95                            54                          112±26     118±27                         120±23     120±22
   Control arm                      95                            49                          115±29     120±24                         116±23     117±23
   P value                                                                                    0.7        0.6                            0.2        0.3
  Central venous pressure (mm Hg)                                                                                                                  
   Experimental arm                 95                            54                          10±5       11±4                           11±4       11±4
   Control arm                      95                            49                          9±4        10±4                           10±4       10±4
   P value                                                                                    0.25       0.2                            0.2        0.2
  Heart rate (beats/min)                                                                                                                           
   Experimental arm                 95                            54                          105±25     101±23                         101±24     98±24
   Control arm                      95                            49                          103±24     99±24                          101±24     100±24
   P value                                                                                    0.6        0.7                            1          0.6
  Lactates (mmol/L)                                                                                                                                
   Experimental arm                 95                            54                          6.6±10     6.4±9.6                        7.3±11.7   7.6±12.9
   Control arm                      95                            49                          6.3±9.0    6.1±8.5                        6.3±8.8    6.8±9.2
   P value                                                                                    0.9        0.9                            0.6        0.7
  PaO~2~/FiO~2~ (mm Hg)                                                                                                                            
   Experimental arm                 95                            54                          180±105    193±114                        199±105    207±112
   Control arm                      95                            49                          196±140    193±127                        193±124    194±113
   P value                                                                                    0.6        1                              0.9        0.5
  ScvO~2~ (%)                                                                                                                                      
   Experimental arm                 95                            54                          74.5±11    76±12                          77±12      77±11
   Control arm                      95                            49                          75±11      74±13                          75±11      74±10
   P value                                                                                    0.6        0.4                            0.5        0.2
  ScvO~2~ \<70% (%)                                                                                                                                
   Experimental arm                 95                            54                          30         21                             22         24
   Control arm                      95                            49                          27         26                             22         22
   P value                                                                                    0.8        1                              0.6        0.6
  Masseter-StO~2~ (%)                                                                                                                              
   Experimental arm                 95                            54                          70±19      72±18                          73±18      71±20
   Control arm                      95                            49                          68±22      67±24                          66±26      62±28
   P value                                                                                    0.7        0.3                            0.15       0.09
  Masseter-StO~2~ \<80% (%)                                                                                                                        
   Experimental arm                 95                            54                          62         59                             51         63
   Control arm                      95                            49                          57         63                             65         74
   P value                                                                                    0.7        0.4                            0.3        0.3
  Deltoid-StO~2~ (%)                                                                                                                               
   Experimental arm                 95                            54                          58±25      59±26                          60±25      57±26
   Control arm                      95                            49                          60±23      59±24                          59±25      55±27
   P value                                                                                    0.7        0.9                            0.8        0.7
  Deltoid-StO~2~ \<80% (%)                                                                                                                         
   Experimental arm                 95                            54                          70         69                             71         79
   Control arm                      95                            49                          77         72                             74         79
   P value                                                                                    0.4        0.8                            0.7        0.9
  Thenar-StO~2~ (%)                                                                                                                                
   Experimental arm                 95                            54                          83±10      83±11                          81±16      81±16
   Control arm                      95                            49                          81±10      79±9                           77±14      78±13
   P value                                                                                    0.3        0.11                           0.17       0.25
  Thenar-StO~2~ \<80% (%)                                                                                                                          
   Experimental arm                 95                            54                          31         32                             26         31
   Control arm                      95                            49                          37         43                             43         54
   P value                                                                                    0.5        0.4                            0.08       0.02
  StO~2~ \>80% over two sites (%)                                                                                                                  
   Experimental arm                 95                            54                          28         39                             40         34
   Control arm                      95                            49                          29         33                             36         23
   P value                                                                                    0.7        0.6                            0.5        0.2

Primary endpoint {#s3c}
----------------

There were 18 (33.3%) patients who died or had a delta SOFA \>0 in the experimental arm on day 7 compared with 14 (28.6%) patients in the control arm (absolute difference 4.8%; 95% CI −0.131 to 0.226; P=0.67) ([table 3](#T3){ref-type="table"}). There were nine (16.7%) deaths in the experimental arm and nine (18.4%) deaths in the control arm (absolute difference: 17%; 95% CI −0.13 to 0.17; P=0.69).

Secondary endpoints {#s3d}
-------------------

There were 32 (31.1%) deaths at study day 30, 17 (31.5%) in the experimental arm and 15 (30.6%) in the control arm (P=0.90) ([table 3](#T3){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). There were no significant differences in the time on vasopressor therapy between groups (5.8±13.5 days in the experimental group vs 4.1±5.8 days in the control group, P=0.40). Thirty-one (57%) patients in the experimental arm and 14 (29%) in the control arm received red cells by day 7 (P=0.01, [table 3](#T3){ref-type="table"}). There was a trend towards higher doses of dobutamine in the experimental group at day 1 (P=0.08, [table 3](#T3){ref-type="table"}). The mean number of days on mechanical ventilation up to 30 days was 12.2±10.6 days in the experimental group and 7.6±7.9 days in the control group (P=0.03) (online [supplementary figure 1](#SP1){ref-type="supplementary-material"}). Thirty-six (66.7%) and 17 (35.5%) patients were on mechanical ventilation in the experimental and control groups, respectively, on day 7 (P\<0.01, OR 3.3, 95% CI 1.2 to 8.7). This difference remained significant after adjustments for age and red cells transfusion (OR 2.9, 95% CI 1.1 to 8.1) There was no significant difference between groups for CVP, systolic blood pressure or heart rate at H6 ([table 2](#T2){ref-type="table"}).
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![Kaplan-Meier survival estimates. Shown is the probability of survival for participants according to randomisation arm at 30 days.](bmjopen-2017-017581f03){#F3}

###### 

Study outcomes

  Outcome                                                                   Experimental arm   Control arm   Incremental effect (95% CI)   P value
  ------------------------------------------------------------------------- ------------------ ------------- ----------------------------- ---------
  Expected number of patients                                               95                 95                                          
  Actual number of patients                                                 54                 49                                          
  Primary outcome: death at day 7 or DSOFA \>0, n (%)                       18 (33.3)          14 (28.6)                                   0.67
    Relative risk                                                                                            1.17 (0.58 to 2.34)           0.67
    Absolute risk reduction                                                                                  −4.7 (−22.6 to 13.1)          
    Unadjusted OR                                                                                            1.25 (0.54 to 2.89)           0.64
    Adjusted OR (on age and gender)                                                                          1.22 (0.52 to 2.87)           0.64
  Secondary outcomes                                                                                                                       
   Death at day 30, n (%)                                                   17 (31.5)          15 (30.6)     1.04 (0.45 to 2.4)            0.9
   Time on vasopressor up to 30 days, days (SD)                             5.8 (13.5)         4.1 (5.8)     1.7 (−2.3 to 5.7)             0.4
   Time on advanced respiratory support up to 30 days, days (SD)            12.2 (10.6)        7.6 (7.9)     4.6 (0.97 to 8.2)             0.03
   Participants infused with dobutamine up to the sixth hour, %             75                 70            1.48 (0.6 to 3.8)\*           0.5
   Mean dobutamine dose in milligrams per hour during day 1, mg/hour (SD)   11.5 (21.3)        5.9 (11.5)    5.6 (−1.2 to 12.4)            0.08†
   Participants who received a transfusion of red cells up to day 7, %      57                 29            3.3 (1.5 to 7.7)\*            0.01

For one patient without a day 7 SOFA score, the last known SOFA score value (day 6 SOFA score) was used for the calculation of the difference (last value carried forward method). Eight patients did not have a baseline SOFA score, so the day 1 value was used as the baseline score.

\*Unadjusted OR.

†Wilcoxon test.

SOFA, Sepsis-related Organ Failure Assessment.

Discussion {#s4}
==========

This trial did not find any evidence for a benefit in survival or organ function from an NIRS-derived StO~2~-guided early goal-directed therapy. There was some evidence that the experimental algorithm of resuscitation was associated with prolonged mechanical ventilation, more blood transfusion and more use of inotropes.

The trial was terminated after the enrolment of 103 patients because of cessation in financial support. This decision was made because the 2009 global economic crisis strongly affected the trial sponsor, Hutchinson Technology. Thereafter, it was not possible to obtain the appropriate probes for StO~2~ monitoring, and the clinical research personnel who assisted with data management were not available. We obtained access to the database in March 2010, and the final statistical report was available before the end of 2011. Thereafter, the study chair (DA) worked for the French government as chief counsellor for the Minister of Health from May 2012 to May 2017, and he could not publish any paper in partnership with health product companies. The direction of the point estimate for the primary outcome did not favour the experimental intervention, and there was a strong indication for harm in the analysis of the secondary outcomes, despite the premature termination of the trial. Trials stopped prematurely for efficacy may result in an overestimation of the effects of an experimental intervention,[@R19] but this trial was stopped as a consequence of the global economic crisis and not because of treatment efficacy.

This study was the first multicentre randomised trial of NIRS-derived StO~2~-guided resuscitation in sepsis or septic shock. We found no evidence to support the addition of muscle StO~2~ as a surrogate of microcirculation evaluation in the early phase of haemodynamic management of patients with sepsis.[@R8] There was no gold standard for microcirculation available to compare our StO~2~-guided strategy. We evaluated a clinical algorithm that included targeting StO~2~ above 80% in at least two different sites. Therefore, the present study did not evaluate the performance of StO~2~ for the diagnosis of microcirculatory dysfunction, but it evaluated the downstream consequences of the use of StO~2~ on clinical outcomes. The experimental strategy of targeting muscle StO~2~ produced no survival benefit and no evidence in favour of the prevention or hastening of the resolution of organ dysfunction.

The experimental algorithm in this trial was similar to previously described algorithms for early goal-directed therapy.[@R20] The experimental algorithm was associated with prolonged mechanical ventilation and a greater number of patients requiring blood product transfusions and dobutamine infusion. Both interventions may improve the microcirculatory function of patients who are critically ill with sepsis,[@R10] but the resuscitation algorithm failed to normalise muscle StO~2~ in most patients. However, the aggressive use of dobutamine[@R21] and red cell transfusion[@R22] is also associated with poor outcomes in ICU patients. The benefits of targeting muscle StO~2~ via interventions other than dobutamine and blood products deserve further investigation. The concept of early goal-directed therapy was challenged in three large sepsis trials.[@R23] The results reflect that the global management of patients has substantially changed since the landmark study of Rivers *et al*.[@R20] However, the treatment strategies tested in these trials did not include microcirculation as a target. Therefore, the recent challenge of early goal-directed therapy may not affect the results of our study.

The inclusion of muscle StO~2~ targets in the quantitative resuscitation protocolised care was associated with prolonged mechanical ventilation, which may have at least partially resulted from increased blood transfusions.[@R22] Notably, the weaning of patients from mechanical ventilation followed current guidelines in both trial arms. This result encourages the monitoring of ventilation length in further studies.

We chose to target skeletal muscle StO~2~ values of 80% or greater because this cut-off corresponded to the lower limit of the 95% CI in healthy volunteers and discriminated between sepsis survivors and non-survivors.[@R26]

We used the commonly accepted NIRS technology to measure StO~2~ [@R5] and recorded StO~2~ from the three different areas to obtain a broader evaluation of tissue oxygenation.[@R12] We used steady-state StO~2~ values rather than values obtained during vascular occlusion tests. The assessment of dynamic changes in StO~2~ during and immediately after limb ischaemia may be more sensitive than steady-state StO~2~ values to detect the extent of microcirculation dysfunction during sepsis.[@R28] However, vascular occlusion test results may depend on the probe and site of measurement,[@R30] and these measurements are cumbersome and inconvenient for serial assessments at very short intervals.[@R31] The vascular occlusion test cannot be used to assess muscle StO~2~ at multiple sites.

A major objective of the initial resuscitation of patients with sepsis is to prevent the deterioration of organ function. The SOFA score is an effective method to describe organ dysfunction/failure in patients who are critically ill. Regular, repeated scoring enables effective monitoring of patient condition and disease development, and it may enable comparisons between patients who would benefit in clinical trials.[@R33]

The delta SOFA score may be used to quantify the degree of dysfunction/failure already present on ICU admission, the degree of dysfunction/failure that appears during the ICU stay and the cumulative insult suffered by the patient. These properties make it a good instrument in the evaluation of organ dysfunction/failure.[@R34]

Patients who exhibit a 1-point increase in SOFA score during the first days of ICU had death rates \>50%, which is markedly higher than patients in whom the SOFA score decreased by 1 point (mortality 23%) or remained unchanged (mortality 31%).[@R35]

The overall recruitment rate of this study was low, primarily because most patients entered the ICU beyond the 8-hour time window from sepsis onset. This trial found that approximately two-thirds of patients with sepsis/septic shock exhibited baseline StO~2~ levels \<80% at two sites, and the vast majority exhibited ScvO~2~ over 70%. These findings confirm that abnormal StO~2~ may be a common feature in sepsis/septic shock. This trial found that the inclusion of StO~2~ \>80% as a target in the algorithm for early goal-directed therapy likely provided no value in clinical outcomes. However, these findings do not exclude a potential benefit of targeting StO~2~ in a different protocol using different cut-off values or treatment strategies. These findings do not exclude a potential benefit of targeting other surrogates of microcirculation. The Surviving Sepsis Campaign guidelines were updated twice,[@R8] and the definition of sepsis was updated once,[@R36] since our trial was performed. The 2016 updated guidelines still include no statement about targeting the microcirculation in sepsis. There are several techniques to measure/monitor microcirculation, but no trials have investigated their usefulness in guiding patient resuscitation.[@R37]

Conclusions {#s5}
===========

The present study ended prematurely due to lack of funding. Nevertheless, the current findings provide no evidence for any potential benefit from targeting muscle StO~2~ in addition to CVP, MAP and ScvO~2~. The targeting of muscle StO~2~ for early goal-directed therapy failed to significantly increase muscle StO~2~ in most patients, and it was associated with prolonged mechanical ventilation, increased blood transfusions and increased doses of dobutamine.
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